Document:

"SUPER CITRIMAX(R) CLINICAL STRENGTH"
                               LICENSING AGREEMENT

This Licensing Agreement ("Agreement") is entered into as of June 7, 2004
("Effective Date"), between InterHealth Nutraceuticals Incorporated, a
California corporation ("Company"), and the licensee identified on the signature
page of this Agreement ("Licensee").

WHEREAS, Company markets, distributes and sells a standardized calcium/potassium
(-)hydroxycitric acid product described in Exhibit A attached hereto
("Product"), which:

     (a)  is sold as nutritional supplement,

     (b)  is the subject of various U.S. and PCT patents pending described in
          Exhibit A attached hereto, as well as other patents pending, which may
          be applied for in the future ("Patents Pending"),

     (c)  is the subject of various research studies described in Exhibit B
          attached hereto, as well as other research studies, which may be
          conducted and published in the future ("Research"),

     (d)  is the subject of various product claims covered by the Patents
          Pending and supported by the Research ("Product Claims"), and

     (e)  is sold under the tradename "Super CitriMax Clinical Strength"
          ("Trademark")

("Licensed Product").

WHEREAS, A) Company is the owner of all right, title and interest in the (i)
Patents Pending, including any continuation-in-parts, divisional and reissue
applications, and any patents resulting therefrom ("Patent Rights"), and (ii)
Trademark, including variations thereof and any registrations which may exist
therefore, for its Licensed Product, B) Licensee desires to sell, market and
distribute finished product(s) that contain Licensed Product to be packaged by
Licensee in end-user, finished packaged form as a nutritional supplement (each a
"Finished Product," collectively "Finished Products"), and to use the Trademark,
Product Claims and Research in connection with sales of its Finished Products;
and C) Company is willing to (i) sell Product to Licensee, or Licensee's
designated contract manufacturer(s), and (ii) grant Licensee the right to use
the Trademark, Product Claims and Research in connection with the sale of
Licensee's Finished Products.

NOW, THEREFORE, the parties agree as follows:

     1.   TRADEMARK OWNERSHIP - Licensee agrees that:

          (a)  Company is the sole and exclusive owner of all right, title and
               interest in, and to, the Trademark and Patent rights;

          (b)  Licensee shall not challenge or question the validity of, or
               Company's title to, the Trademark or Patent Rights; and

          (c)  with the exception of the rights being licensed under this
               Agreement, all other rights relating to the Trademark and Patent
               Rights are the property of the Company and Licensee shall not
               acquire any other rights to the Trademark or Patent Rights.

     2.   BUY/SELL AGREEMENT - Company agrees to sell Product to Licensee or
          Licensee's designated contract manufacturer(s) of Finished Products
          (each a "Contract Manufacturer," collectively "Contract
          Manufacturers"), and Licensee or Licensee's Contract Manufacturers,
          whichever the case may be, agree to purchase Product exclusively from
          Company at prices, terms and conditions acceptable to Company and
          Licensee and/or Licensee's Contract Manufacturers, whichever the case
          may be, and other terms and conditions specified in this Agreement.

     3.   GRANT OF LICENSE - Company grants to Licensee, and Licensee accepts, a
          non-exclusive, non-transferable, royalty-free license to use the
          Trademark, Product Claims and Research solely in connection with the
          marketing and distribution of Finished Products that contain Product
          in the manner, and on the terms and conditions, specified in this
          Agreement. InterHealth represents that to the best of its knowledge,
          information, and belief (a) the Research has been conducted in
          accordance with good scientific standards and practices, and (b) the
          Product Claims are substantiated by the Research.

     4.   USE OF TRADEMARK - Licensee shall:

          (a)  use the Trademark, Product Claims and Research solely in
               connection with:

               (i)  the Licensed Product purchased from Company, and

               (ii) Finished Product that is in compliance with this Agreement;

          (b)  display the Trademark on, or in, all labeling, advertising and
               promotional

               materials of its Finished Products in a manner that clearly
               associates the Trademark with the licensed Product;

          (c)  display or reproduce the Trademark only in:

               (i)  the appropriate logo style specified in Exhibit C attached
                    to this Agreement (electronic file of the Trademark logo to
                    be provided to Licensee by Company upon execution of this
                    Agreement); or

               (ii) type-written form only if used in secondary labeling,
                    advertising and promotional copy (i.e. in a sentence or
                    paragraph describing the Licensed Product), and so long as
                    the Super CitriMax trademark is accompanied by the "(R)"
                    symbol and identified as a trademark of InterHealth N.I.;
                    and

          (d)  not use, display or relate in any manner, either directly or
               indirectly, the Trademark, Product Claims or Research in
               connection with any products that do not contain Licensed Product
               and are not subject to this Agreement.

     5.   PRODUCT INFORMATION AND MATERIALS - Company provides, and will
          provide, Licensee information and materials relating to Licensed
          Product, whether proprietary or non-proprietary, whether written,
          recorded or verbal, whether on, prior or subsequent to the date of
          this Agreement, whether prepared by Company or by a third party,
          including, but not limited to, all Licensed Product sales and
          marketing materials, research data and other technical information in
          good faith and which InterHealth believes to be true and accurate
          ("Information" and "Materials"), "As Is, With All Faults," and makes,
          and will make, no representations or warranties, express or implied,
          as to the usefulness, accuracy, completeness, feasibility, reliability
          or legality of the Information and Materials. Licensee may use all
          Information and Materials prepared by or for Company solely in
          connection with the marketing and distribution of Licensed Product
          purchased from the Company or Finished Products that contain Licensed
          Product purchased from the Company and not in connection with any
          products that do not contain Licensed Product and are not subject to
          this Agreement; provided that Licensee does not in any way alter any
          of the Materials. Company may amend, add to, subtract from or
          otherwise change from time to time, the Information and/or Materials,
          in its sole and absolute discretion.

     6.   UNDERTAKINGS BY LICENSEE:

          (A)  PRODUCT CHANGES - Licensee may amend, add to, subtract from or
               otherwise change from time to time its Finished Products,
               provided that all such changes and Finished Products comply with
               the terms and conditions of this Agreement;

          (B)  PRODUCT DOSAGE - Licensee shall formulate, manufacture and label
               all Finished Product in accordance with the required dosage
               described in Exhibits A ("Required Dosage");

          (C)  LABELING STATEMENTS - Licensee shall display the required
               labeling statements described in Exhibits A ("Required Labeling
               Statements"), on or in all labeling, advertising and promotional
               materials of its Finished Products in a manner that clearly
               associates the Required Labeling Statements with the Licensed
               Product;

          (D)  PATENTS - If and when they are issued, Licensee shall list the
               number(s) of all patents issued for Licensed Product ("Patents"),
               which are appropriate to the territory(ies) in which the Finished
               Product is sold, on or in all labeling, advertising and
               promotional materials of said Finished Products in a manner that
               clearly associates the Patents with the Licensed Product
               ("Required Patent Information"). As new Patents are issued, or
               the Required Patent Information changes, Company shall notify
               Licensee in writing and Licensee shall be provided a reasonable
               amount of time to update its labeling, advertising and
               promotional materials of its Finished Products to reflect the new
               Required Patent Information;

          (E)  LABEL REVIEW - Prior to distribution of its Finished Products,
               Licensee shall provide Company copies of its Finished Product
               labeling, advertising and promotional materials for pre-market
               approval by Company, which Company shall promptly review solely
               with respect to their compliance with this Agreement. Company
               shall promptly notify Licensee in writing of its acceptance or
               rejection of Licensee's Finished Product labeling, advertising
               and promotional materials with respect to their compliance with
               this Agreement. If rejected, Company shall inform Licensee of the
               changes necessary to be in compliance with this Agreement;

          (F)  PRODUCT QUALITY - Licensee shall (i) not blend nor formulate the
               Licensed Product with any other (-)hydroxycitric acid or Garcinia
               material, and (ii) not sell any Finished Products that are not
               manufactured in accordance with the requirements of the United
               States Federal Food, Drug and Cosmetic Act, including all
               applicable good manufacturing practice regulations, or, in the
               event Finished Products are manufactured or distributed in
               countries outside the United States, in accordance with all
               applicable laws and regulations of such countries;

          (G)  PRODUCT SUPPLY - Licensee agrees that it will not resell or
               supply any Licensed Product in bulk raw material form, either
               directly or indirectly, to any other third party, except for use
               in the manufacture of Licensee's Finished Products;

          (H)  SALES RECORDS - If requested by Company, Licensee shall provide
               Company a record of its Finished Product sales within fifteen
               (15) days of Company's written request. Company shall, at its
               sole option, have the right, at its own expense, to have an
               independent accounting firm acceptable to Licensee, whose
               acceptance shall not unreasonably be withheld, audit Licensee's
               Finished Product sales records during regular business hours, no
               more than once each calendar year and with at least five (5)
               business days prior written notice.

          (I)  THIRD PARTY COMPLIANCE - Licensee shall assure compliance with
               this Agreement by any third-party manufacturer or distributor of
               Finished Products, and guarantees performance of and payment
               under Company's General Purchase Agreement by any manufacturer
               which has purchased Licensed Product from Company for the
               manufacture of Finished Products under contract with Licensee;

          (J)  NEW MARKS - Licensee may use its own trademarks, tradenames,
               logos, advertising slogans and other related marks to identify
               Licensee and its Finished Products (collectively, "Other Marks")
               in Licensee's Materials, but agrees not to combine the Trademark
               with any Other Marks, words, letters or symbols, or otherwise
               alter the Trademark, to form one or more new marks ("New Marks"),
               without the express written consent of Company, which consent
               Company may withhold at its sole and absolute discretion.
               Licensee agrees that Company is the sole and exclusive owner of
               all right, title and interest in, and to, any New Marks, except
               those rights expressly granted to Licensee;

          (K)  TRADEMARK INFRINGEMENT - Licensee shall bring to the attention of
               Company any infringement or misuse of the Trademark which comes
               to Licensee's attention. Company shall indemnify, defend and hold
               Licensee harmless from any infringement or unfair competition
               proceedings involving the Trademark so long as Licensee is using
               the Trademark in compliance with this Agreement. Licensee shall
               not assert any claim based upon misuse or infringement of the
               Trademark without the prior written consent of Company;

          (L)  COMPLIANCE WITH LAWS - Licensee will comply with all laws and
               regulations relating or pertaining to the use of the Trademark
               and marketing of Finished Products;

          (M)  EXPENSES - Licensee will not create any expenses chargeable to
               Company; and

          (N)  INDEMNIFICATION - Except as provided in Section 5(k), Licensee
               indemnifies and holds Company harmless from any claims arising
               out of any act under or in violation of this Agreement by
               Licensee and its manufacturers and/or distributors, including,
               but not limited to, the distribution, advertising and promotion
               of Licensee's Finished Products, or use of the Information or
               Materials.

          (O)  FORMULATION EXCLUSION - Licensee shall not produce, market or
               sell any Finished Product(s) that contain a combination of
               (-)hydroxycitric acid (Garcinia), chromium and gymnemic acid
               (Gymnema) material, without the express written consent of
               Company.

     7.   TERM AND TERMINATION - This Agreement shall commence on the Effective
          Date and shall continue in full force and effect, unless and until
          terminated as follows:

          (a)  Company shall have the right to terminate this Agreement upon
               written notice to Licensee upon the breach of any provision of
               this Agreement,

          (b)  Licensee shall have the right to terminate this Agreement at any
               time upon written notice to Company, or

          (c)  Licensee's failure to purchase Licensed Product from Company
               during any consecutive twelve month period of time shall
               constitute on abandonment and automatic termination of this
               Agreement.

          Upon termination of this Agreement for any reason, Licensee shall
          immediately discontinue all use of the Trademark, Product Claims,
          Research, Materials and Information, except for publicly available,
          non-proprietary Information. Sections 6(k,m,n,o), 7 and 8 shall
          survive the termination of this Agreement.

     8.   GENERAL PROVISIONS:

          (A)  ASSIGNMENT - This Agreement is personal to Licensee. Licensee
               shall not assign or transfer any rights or obligations under this
               Agreement without the prior written consent of Company; provided,
               however, that Licensee may assign to any manufacturer with which
               Licensee contracts to produce any Finished Products any rights or
               obligations reasonably necessary to enable the manufacturer to
               produce the Finished Products. Any purported assignment without
               consent except as provided in this Section 8(a) will be null and
               void. This Agreement shall inure to the benefit of and be binding
               upon the parties and their successors and assigns;

          (B)  RELATIONSHIP - The relationship of the parties to this Agreement
               is determined solely by the provisions of this Agreement. The
               parties do not intend to create any agency, partnership, joint
               venture, trust or other relationship with duties or incidents
               different from those of parties to an arm's-length contract

          (C)  CHOICE OF LAW - This Agreement shall be construed in accordance
               with, and governed by, the internal laws of the State of
               California, without regard to conflicts of law;

          (D)  INTEGRATION - This Agreement sets forth the entire understanding
               of the parties relating to the transactions it contemplates, and
               supersedes all prior understandings relating to them, whether
               written or oral. There are no obligations, commitments,
               representations or warranties relating to them except those
               expressly set forth in these Agreements;

          (E)  ATTORNEY'S FEES - if any action is necessary to enforce the terms
               of this Agreement the prevailing party shall be entitled to
               reasonable attorneys' fees in addition to any other relief to
               which it may be entitled;

          (F)  SEVERABILITY - Should all or any portion of any provision of this
               Agreement be held unenforceable or invalid for any reason, the
               remaining portions or provisions shall be unaffected; and

          (G)  WEIVER/MODIFICATION/ AMENDMENT - No amendment of, supplement to
               or waiver of any obligations under this Agreement will be
               enforceable or admissible unless set forth in a writing signed by
               the party against which enforcement or admission is sought. No
               delay or failure to require performance of any provision of this
               Agreement shall constitute a waiver of that provision as to that
               or any other instance. Any waiver granted shall apply solely to
               the specific instance expressly stated.

IN WITNESS WHEREOF the parties have executed this Agreement as of the date
first written above.

LICENSEE

Company: Creative Enterprises Intl., Inc.
A Nevada Corporation
Address: 825 Lafayette Road
City, State, Zip: Bryn Mawn, Pa. 19010

Signature: /s/ Michael Salaman
           --------------------------
Name (Print): Michael Salaman
Title: President

COMPANY (INTERHEALTH)

SIGNATURE: /s/ Illegible
           --------------------------
Name (Print): _______________________
Title: EXEC. VP

                               EXHIBIT A - PRODUCT

PRODUCT NAME                        Super CitriMax(R) Clinical Strength

DESCRIPTION                         High solubility, non-hygroscopic, low
                                    sodium, potassium/calcium salt of
                                    (-)hydroxycitric acid extract, from the
                                    dried fruit rind of Garcinia cambogia
                                    (patent pending).

PRODUCT TYPES

   HCA-600-SXG                      Coarse powder for tableting and some
                                    encapsulating applications.

   HCA-6OO-SXM                      Medium mesh powder for multipurpose
                                    applications.

   HCA-600-SXS                      Soluble fine powder for food and beverage
                                    and some encapsulating applications.

SPECIFICATIONS*

   (-)Hydroxycitric Acid (mg/g)     600 +/- 50
   Calcium (mg/g)                   110 +/- 30
   Potassium (mg/g)                 160 +/- 40
   Sodium (mg/g)                    Less than 10

* For additional specifications, see Company's HCA-600-SXG, -SXM and -SXS
product specification sheets.

REQUIRED DOSAGE

   For dietary supplements          4500 mgs material providing 2700 mgs
                                    (-)hydroxycitric acid per day taken in three
                                    divided doses 30-60 minutes before meals.

   For functional foods and         1500 mgs material providing 900 mgs
   beverages                        (-)hydroxycitric acid per serving.
                                    Recommended three servings per day.

REQUIRED LABELING STATEMENTS

   (See Super CitriMax(R)           Super CitriMax(R) is a trademark of
   Clinical Strength Labeling       InterHealth N.I.
   Guidelines for correct usage     Super CitriMax brand of (-)hydroxycitric
   of Required Labeling             acid (patents-pending).
   Statements.)

REQUIRED PATENT INFORMATION*

     All countries         Patents-pending

     * To be listed in the Required Labeling Statement as indicated above or
     elsewhere in the labeling, advertising and promotional materials of
     Licensee's Finished Products in a manner that clearly associates the
     Patents and/or Patents Pending with the Licensed Product.

SUPER CITRIMAX CLINICAL STRENGTH LICENSING AGREEMENT
                                              FORM SCX-CS-TLA.DOC--March 3, 2004

                              EXHIBIT B - RESEARCH

PUBLICATIONS

     1.   Ohia SE, Awe O, LeDay AM, Opere CA, Bagchi D, Effect of Hydroxycitric
          Acid on Serotonin Release from Isolated Rat Brain Cortex, Research
          Communications in Molecular Pathology and Pharmacology,
          109:210-216, 2001.

     2.   Loe YC, Bergeron N, Rodriguez N, Schwarz J-M, Gas Chromatography/Mass
          Spectrometry Method to Quantify Blood Hydroxycitrate Concentration,
          Analytical Biochemistry, 292:148-154, 2001.

     3.   Westerterp-Plantenga MS, Kovacs EMR, The Effect of (-)-Hydroxycitrate
          on Energy Intake and Satiety in Overweight Humans. International
          Journal of Obesity, 26:870-872, 2002.

     4.   Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Stohs SJ, Safety and
          Mechanism of Appetite Suppression by a Novel Hydroxycitric Acid
          Extract (HCA-SX), Molecular and Cellular Biochemistry, 238: 89-103,
          2002.

     5.   Shara M, Ohia SE, Yasmin T, Zardetto-Smith A, Kincaid A, Bagchi M,
          Chatterjee A, Bagchi D, Stohs SJ, Dose- and Time-Dependent Effects of
          a Novel (-)-Hydroxycitric Acid Extract on Body Weight, Hepatic and
          Testicular Lipid Peroxidation, DNA Fragmentation and Histopathological
          Data over a Period of 90 D, Molecular and Cellular Biochemistry,
          254:339-346, 2003.

     6.   Preuss HG, Bagchi D, Bagchi M, Rao CVS, Satyanarayana S, Dey DK,
          Efficacy of a Novel, Natural Extract of (-)-Hydroxycitric Acid
          (HCA-SX) and a Combination of HCA-SX, Niacin-Bound Chromium and
          Gymnema sylvestre Extract in Eight Management in Human Volunteers,
          Nutrition Research 24:45-58, 2004.

     7.   Preuss HG, Bagchi D, Bagchi M, Rao CVS, Dey DK and Satyanarayana S,
          Efficacy of a Novel, Natural Extract of (-)-Hydroxycitric Acid
          (HCA-SX) and a Combination of HCA-SX, Niacin-Bound Chromium and
          Gymnema sylvestre Extract in Weight Loss, Diabetes, Obesity and
          Metabolism (In Press).

     8.   Shara M, Ohia SE, Schmidt RE, Yasmin T, Zardetto-Smith A, Kincaid A,
          Bagchi M, Chatterjee A, Bagchi D and Stohs SJ, Physico-chemical
          Properties of a Novel (-)-Hydroxycitric Acid Extract and Its Dose-and
          Time-dependent Effects on body Weight, Selected Organ Weights, Hepatic
          Lipid Peroxidation and DNA Fragmentation, Hematology and Clinical
          Chemistry, and Histopathological Changes Over a Period of 90 Days,
          Molecular and Cellular Biochemistry (In Press).

ABSTRACTS

     1.   Loe YC, Rodriguez N, Schwarz J-M, A New Mass Spectrometric Method to
          Quantify Blood Hydroxycitrate Concentration in Human Subjects, The
          FASEB Journal, 14:A212, Abs. 158.1, 2000.

     2.   Loe YC, Bergeron N, Phan J, Wen M, Lee J, Schwarz J-M, Time Course of
          Hydroxycitrate Clearance in Fasting and Fed Humans, The FASEB Journal,
          15:A632, Abs. 501.1, 2001.

     3.   Ohia SE, Awe SO, LeDay AM, Bagchi D, Effect of Hydroxycitric Acid on
          [(3)H]-5-HT Release from Rat Brain Cortex, The FASEB Journal, 15:A224,
          Abs. 207.13, 2001.

     4.   Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Mechanism of Appetite
          Suppresion by a Novel, Natural Hydroxycitric Acid, The Toxicologist,
          66 (1-S):188-189, Abs. 921, 2002.

     5.   Preuss HG, Bagchi D, Rao CVS, Echard BW, Satyanarayana S, Bagchi M,
          Effect of Hydroxycitric Acid on Weight Loss, Body Mass Index and
          Plasma Leptin Levels in Human Subjects, The FASEB Journal 16:A1020,
          Abs. 742.16, 2002.

     6.   Bagchi D, Preuss HG, Ohia SE, Rao CVS, Satyanarayana S, Bagchi M,
          Weight Management and Mechanism of Appetite Suppression by a Novel,
          Natural Extract of (-)-Hydroxycitric Acid, International Scientific
          Conference on Complimentary, Alternative & Integrative Medicine
          Research-Harvard University, Boston, MA, 9, Abs. 141, April
          12-14, 2002.

     7.   Bagchi D, Preuss HG, Rao CVS, Satyanarayana S, Bagchi M, Weight
          Management and Mechanisms of Action of a Novel, Natural Extract of
          (-)-Hydroxycitric Acid (HCA-SX) and a Combination of HCA-SX

SUPER CITRIMAX CLINICAL STRENGTH LICENSING AGREEMENT
                                              FORM SCX-CS-TLA.DOC--March 3, 2004

          Plus Niacin-Bound Chromium (NBC) and Gymnema sylvestre Extract (GSE),
          9th International Congress on Clinical Nutrition, London, UK, Abs.
          AB041, June 24-26, 2002.

     8.   Bagchi M, Preuss HG, Rao CVS, Bagchi D, Efficacy of a novel
          (-)-Hydroxycitric Acid Extract in Weight Management, Journal of the
          American College of Nutrition, 21:481, Abs. 61, 2002.

     9.   Bagchi D, Preuss HG, Rao CVS, Satyanarayana S, Bagchi M, Mechanisms of
          Weight Management by a Novel, Natural Extract of (-)-Hydroxycitric
          Acid (HCA-SX) and a Combination of HCA-SX Plus Niacin-Bound Chromium
          (NBC) and Gymnema sylvestre Extract (GSE), Journal of Tumor Marker
          Oncology, 17:55, Abs. A18, 2002.

     10.  Bagchi D, Preuss HG, Ohia SE, Rao CVS, Satyanarayana S and Bagchi M,
          Weight Management and Mechanism of Appetite Suppression by a Novel,
          Natural Extract of (-)-Hydroxycitric Acid, International Scientific
          Conference on Complementary, Alternative & Integrative Medicine
          Research, Boston, MA, April 12-14, 2002.

     11.  Debasis B, Weight Management & Mechanism of Appetite Suppression by a
          Natural Extract of (-)-Hydroxycitric Acid & a Combination of HCA-SX
          Plus Niacin-Bound Chromium (NBC) & Gymnema Sylvestre Extract (GSE),
          American Society of Bariatric Physicians Western Regional Obesity
          Course, Denver, CO, May 16-18, 2002.

     12.  Bagchi D, Preuss HG, Ohia SE, Rao CVS, Satyanarayana S and Bagchi M,
          Mechanism of Weight Management by a Novel, Natural Extract of
          (-)-Hydroxycitric Acid (HCA-SX) and a Combination of HCA-SX Plus
          Niacin-Bound Chromium (NBC) and Gymnema Sylvestre Extract (GSE), The
          2nd International Conference on Mechanisms and Actions of
          Nutraceuticals, Krems - Danube, Austria, October 6-9, 2002.

     13.  Ohia SE, Stohs SJ, Shara M, Yasmin T, Chatterjee A, Bagchi M,
          Zardetto-Smith A, Kincaid A and Bagchi D, 90-Day Chronic Toxicity
          Study of a Novel (-)-Hydroxycitric Acid Extract of Garcinia Cambogia,
          Society of Toxicology 42nd Annual Meeting & ToxExpo, Salt Lake City,
          Utah, March 9-13, 2003.

     14.  Bagchi D, Preuss HG, Ohia SE and Bagchi M, Molecular Mechanisms of
          Weight Management by a Novel, Natural Extract of (-)-Hydroxycitric
          Acid, 2003 American Association of Integrative Medicine (AAIM)
          National Conference San Antonio, TX, August 22-24, 2003.

SUPER CITRIMAX CLINICAL STRENGTH LICENSING AGREEMENT
                                              FORM SCX-CS-TLA.DOC--March 3, 2004

                           EXHIBIT C - TRADEMARK LOGO

Logo style for use in conjunction with Licensed Product (contact InterHealth for
electronic file):

[SuperCitrimax(R) LOGO]
Clinical Strength

SUPER CITRIMAX CLINICAL STRENGTH LICENSING AGREEMENT
                                              FORM SCX-CS-TLA.DOC--March 3, 2004

                       SUPER CITRIMAX(R) CLINICAL STRENGTH
                              MARKETING AGREEMENT

This agreement ("Agreement") is entered into this 9th day of June, 2004 by
InterHealth Nutraceuticals Incorporated, a California Corporation with its
principal place of business at 5451 Industrial Way, Benicia, CA 94510
("InterHealth") and Creative Enterprises Intl., Inc., a Nevada corporation with
its principal place of business at 825 Lafayette Road, Bryn Mawr, PA 19010
("Customer").

Whereas, InterHealth markets, distributes and sells a nutritional weight loss
ingredient under the tradename "Super CitriMax(R) Clinical Strength"
("Trademark"), which (a) is sold as a nutritional supplement, (b) is the subject
of certain patents pending ("Patents Pending"), and (c) meets the specifications
described in Exhibit A attached hereto, which may be updated in writing by
InterHealth from time to time (collectively referred to as "Product");

Whereas, Customer wishes to sell, market and distribute Product to be packaged
by Customer in end-user, finished packaged form as a nutritional supplement in
bottled water form only ("Finished Product") through Mass Market ("Channel")
located in the Untied States of America and it territories, Croatia, Australia,
Malaysia, Austria, Mexico, Belgium, New Zealand, Canada, Poland, Czech Republic,
Russia, Finland, South Africa, France, Sweden, Germany, Taiwan, Hong Kong,
Thailand, Japan, The Netherlands, Korea, United Kingdom ("Territory"); and

Whereas, InterHealth appoints Customer to sell Finished Product on a
non-exclusive basis in the Channel and in the Territory.

Customer agrees to:

     1.   Use commercially reasonable efforts to sell, distribute, advertise and
          promote Finished Product in the Channel and in the Territory solely
          under its Skinny Water brand.

     2.   Execute and comply with the terms of the Super CitriMax(R) Clinical
          Strength Licensing Agreement, including but not limited to, (a)
          Finished Product dosage and recommended use requirements, and (b)
          Finished Product labeling requirements, including (i) displaying the
          Trademark logo and identifying the Trademark as "a trademark of
          InterHealth N.I.," (ii) using the term "patent pending" in describing
          the Product, and (iii) listing all Patent numbers, as they are issued,
          on all packaging, advertising and promotional materials of Finished
          Product.

InterHealth agrees to:

     1.   Use commercially reasonable efforts to promptly fill Customer's orders
          for Product and to supply Product to Customer according to
          specifications.

     2.   Use commercially reasonable efforts to provide (a) technical support
          to Customer regarding Product, including information about the
          Product's safety and efficacy, physical and chemical properties, and
          applications and uses, and (b) ongoing marketing, research and
          intellectual property support for Product, to the extent InterHealth
          deems prudent.

     3.   Sell Product to Customer at the price of [****] F.O.B. Benicia,
          CA 94510. Said price shall apply to sales of Product to Customer,
          which are intended for use in the manufacture of Finished Product
          under the Skinny Water brand to be sold in the Channel and in the
          Territory only, and is subject to change upon 30 days written notice.

[*Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.]

______________________________________________________________________

___________                   ___________

/s/ Illegible        6/4/04   /s/ Illegible       6/22/04
------------------    Date    -----------------     Date
__________________            _________________PROMISSORY NOTE

-----------------------------------------------------------------------------------------------------------------------------------
   PRINCIPAL           LOAN DATE           MATURITY           LOAN NO.        CALL/COLL       ACCOUNT       OFFICER       INITIALS
 $500,000.00          03-01-2005                                             (G4AO)                           DOC
-----------------------------------------------------------------------------------------------------------------------------------
                            References in the shaded area are for Lender's use only and do not limit the
                                   applicability of this document to any particular loan or item.
                           Any item above containing ***** has been omitted due to text length limitations.
-----------------------------------------------------------------------------------------------------------------------------------

BORROWER: CREATIVE ENTERPRISES INTERNATTONAL, INC.               LENDER:  MADISON BANK A DIVISION OF LEESPORT BANK
          825 LAFAYETTE ROAD                                              1767 SENTRY WEST
          BRYN MAWR, PA 19010                                             BLUE BELL, PA 19422

===================================================================================================================================

     PRINCIPAL AMOUNT: $500,000.00                       INITIAL RATE: 6.500%               DATE OF NOTE: MARCH 1, 2005

PROMISE TO PAY. CREATIVE ENTERPRISES INTERNATIONAL, INC. ("BORROWER") PROMISES
TO PAY TO MADISON BANK A DIVISION OF LEESPORT BANK ("LENDER"), OR ORDER, IN
LAWFUL MONEY OF THE UNITED STATES OF AMERICA, ON DEMAND, THE PRINCIPAL AMOUNT
OF FIVE HUNDRED THOUSAND & 00/100 DOLLARS ($500,000.00), TOGETHER WITH INTEREST
ON THE UNPAID PRINCIPAL BALANCE FROM MARCH 1, 2005, UNTIL PAID IN FULL.

PAYMENT. BORROWER WILL PAY THIS LOAN IMMEDIATELY UPON LENDER'S DEMAND. PAYMENT
IN FULL IS DUE IMMEDIATELY UPON LENDER'S DEMAND. BORROWER WILL PAY REGULAR
MONTHLY PAYMENTS OF ALL ACCRUED UNPAID INTEREST DUE AS OF EACH PAYMENT DATE,
BEGINNING APRIL 1, 2005, WITH ALL SUBSEQUENT INTEREST PAYMENTS TO BE DUE ON THE
SAME DAY OF EACH MONTH AFTER THAT. UNLESS OTHERWISE AGREED OR REQUIRED BY
APPLICABLE LAW, PAYMENTS WILL BE APPLIED FIRST TO ANY ACCRUED UNPAID INTEREST;
THEN TO PRINCIPAL; THEN TO ANY UNPAID COLLECTION COSTS; AND THEN TO ANY LATE
CHARGES. THE ANNUAL INTEREST RATE FOR THIS NOTE IS COMPUTED ON A 365/360 BASIS;
THAT IS, BY APPLYING THE RATIO OF THE ANNUAL INTEREST RATE OVER A YEAR OF 360
DAYS, MULTIPLIED BY THE OUTSTANDING PRINCIPAL BALANCE, MULTIPLIED BY THE ACTUAL
NUMBER OF DAYS THE PRINCIPAL BALANCE IS OUTSTANDING. BORROWER WILL PAY LENDER
AT LENDER'S ADDRESS SHOWN ABOVE OR AT SUCH OTHER PLACE AS LENDER MAY DESIGNATE
IN WRITING.

VARIABLE INTEREST RATE. The interest rate on this Note is subject to change from
time to time based on changes in an index which is Lender's Prime Rate (the
"Index"). This is the rate Lender charges, or would charge, on 90-day unsecured
loans to the most creditworthy corporate customers. This rate may or may not be
the lowest rate available from Lender at any given time. Lender will tell
Borrower the current Index rate upon Borrower's request. The interest rate
change will not occur more often than each DAY. Borrower understands that Lender
may make loans based on other rates as well. The index currently is 5.500% per
annum. The interest rate to be applied to the unpaid principal balance of this
Note will be at a rate of 1.000 percentage point over the Index, resulting in an
initial rate of 6.500% per annum. NOTICE: Under no circumstances will the
interest rate on this Note be more than the maximum rate allowed by applicable
law.

PREPAYMENT. Borrower may pay without penalty all or a portion of the amount owed
earlier than it is due. Early payments will not, unless agreed to by Lender in
writing, relieve Borrower of Borrower's obligation to continue to make payments
under the payment schedule. Rather, early payments will reduce the principal
balance due. Borrower agrees not to send Lender payments marked "paid in full",
"without recourse", or similar language. If Borrower sends such a payment,
Lender may accept it without losing any of Lender's rights under this Note, and
Borrower will remain obligated to pay any further amount owed to Lender. All
written communications concerning disputed amounts, including any check or other
payment instrument that indicates that the payment constitutes "payment in full"
of the amount owed or that is tendered with other conditions or limitations or
as full satisfaction of a disputed amount must be mailed or delivered to:
MADISON BANK A DIVISION OF LEESPORT BANK, 1767 SENTRY WEST, BLUE BELL, PA 19422.

LATE CHARGE. If a regularly scheduled interest payment is 10 days or more late,
Borrower will be charged 8.000% of the unpaid portion of the regularly scheduled
payment or $15.00, whichever is greater. If Lender demands payment of this loan,
and Borrower does not pay the loan in full within 10 days after Lender's demand,
Borrower also will be charged either 8.000% of the unpaid portion of the sum of
the unpaid principal plus accrued unpaid interest or $15.00, whichever is
greater.

INTEREST AFTER DEFAULT. Upon default, including failure to pay upon final
maturity, Lender, at its option, may, if permitted under applicable law,
increase the variable interest rate on this Note to 6.000 percentage points
over the Index. The interest rate will not exceed the maximum rate permitted by
applicable law. If judgment is entered in connection with this Note, interest
will continue to accrue on this Note after judgment at the interest rate
applicable to this Note at the time judgment is entered.

DEFAULT. Each of the following shall constitute an event of default ("Event of
Default") under this Note.

     PAYMENT DEFAULT. Borrower fails to make any payment when due under this
     Note.

     OTHER DEFAULTS. Borrower fails to comply with or to perform any other term,
     obligation, covenant or condition contained in this Note or in any of the
     related documents or to comply with or to perform any term, obligation,
     covenant or condition contained in any other agreement between Lender and
     Borrower.

     FALSE STATEMENTS. Any warranty, representation or statement made or
     furnished to Lender by Borrower or on Borrower's behalf under this Note or
     the related documents is false or misleading in any material respect,
     either now or at the time made or furnished or becomes false or misleading
     at any time thereafter.

     INSOLVENCY. The dissolution or termination of Borrower's existence as a
     going business, the insolvency of Borrower, the appointment of a receiver
     for any part of Borrower's property, any assignment for the benefit of
     creditors, any type of creditor workout, or the commencement of any
     proceeding under any bankruptcy or insolvency laws by or against Borrower.

     CREDITOR OR FORFEITURE PROCEEDINGS. Commencement of foreclosure or
     forfeiture proceedings, whether by judicial proceeding, self-help,
     repossession or any other method, by any creditor of Borrower or by any
     governmental agency against any collateral securing the loan. This includes
     a garnishment of any of Borrower's accounts, including deposit accounts,
     with Lender. However, this Event of Default shall not apply if there is a
     good faith dispute by Borrower as to the validity or reasonableness of the
     claim which is the basis of the creditor or forfeiture proceeding and if
     Borrower gives Lender written notice of the creditor or forfeiture
     proceeding and deposits with Lender monies or a surety bond for the
     creditor or forfeiture proceeding, in an amount determined by Lender, in
     its sole discretion, as being an adequate reserve or bond for the dispute.

     EVENTS AFFECTING GUARANTOR. Any of the preceding events occurs with respect
     to any Guarantor of any of the indebtedness or any Guarantor dies or
     becomes incompetent, or revokes or disputes the validity of, or liability
     under, any guaranty of the indebtedness evidenced by this Note. In the
     event of a death, Lender, at its option, may, but shall not be required to,
     permit the Guarantor's estate to assume unconditionally the obligations
     arising under the guaranty in a manner satisfactory to Lender, and, in
     doing so, cure any Event of Default.

     CHANGE IN OWNERSHIP. Any change in ownership of twenty-five percent (25%)
     or more of the common stock of Borrower.

     ADVERSE CHANGE. A material adverse change occurs in Borrower's financial
     condition, or Lender believes the prospect of payment or performances of
     this Note is impaired.

     INSECURITY. Lender in good faith believes itself insecure.

                                PROMISSORY NOTE
                                  (CONTINUED)                            Page 2
================================================================================

     CURE PROVISIONS. If any default, other than a default in payment or failure
     to satisfy Lender's requirement in the insufficient Market Value of
     Securities section is curable and if Borrower has not been given a notice
     of a breach of the same provision of this Note within the preceding twelve
     (12) months, it may be cured if Borrower, after receiving written notice
     from Lender demanding cure of such default: (1) cures the default within
     fifteen (15) days; or (2) if the cure requires more than fifteen (15) days,
     immediately initiates steps which Lender deems in Lender's sole discretion
     to be sufficient to cure the default and thereafter continues and completes
     all reasonable and necessary steps sufficient to produce compliance as soon
     as reasonably practical.

LENDER'S RIGHTS. Upon Lender's demand, Lender may, after giving such notices as
required by applicable law, declare the entire unpaid principal balance on this
Note and all accrued unpaid interest immediately due, and then Borrower will
pay that amount.

ATTORNEYS' FEES; EXPENSES. Lender may hire or pay someone else to help collect
this Note if Borrower does not pay. Borrower will pay Lender that amount. This
includes, subject to any limits under applicable law, Lender's attorneys' fees
and Lender's legal expenses, whether or not there is a lawsuit, including
attorneys' fees, expenses for bankruptcy proceedings (including efforts to
modify or vacate any automatic stay or injunction), and appeals. If not
prohibited by applicable law, Borrower also will pay any court costs, in
addition to all other sums provided by law.

JURY WAIVER. Lender and Borrower hereby waive the right to any jury trial in
any  action, proceeding, or counterclaim brought by either Lender or Borrower
against the other.

GOVERNING LAW. This Note will be governed by, construed and enforced in
accordance with federal law and the laws of the Commonwealth of Pennsylvania.
This Note has been accepted by Lender in the Commonwealth of Pennsylvania.

CHOICE OF VENUE. If there is a lawsuit, Borrower agrees upon Lender's request
to submit to the jurisdiction of the courts of MONTGOMERY County, Commonwealth
of Pennsylvania.

DISHONORED ITEM FEE. Borrower will pay a fee to Lender of $30.00 if Borrower
makes a payment on Borrower's loan and the check or preauthorized charge with
which Borrower pays is later dishonored.

RIGHT OF SETOFF. To the extent permitted by applicable law, Lender reserves a
right of setoff in all Borrower's accounts with Lender (whether checking,
savings, or some other account). This includes all accounts Borrower holds
jointly with someone else and all accounts Borrower may open in the future.
However, this does not include any IRA or Keogh accounts, or any trust accounts
for which setoff would be prohibited by law. Borrower authorizes Lender, to
the extent permitted by applicable law, to charge or setoff all sums owing on
the indebtedness against any and all such accounts.

SUCCESSOR INTERESTS. The terms of this Note shall be binding upon Borrower, and
upon Borrower's heirs, personal representatives, successors and assigns, and
shall inure to the benefit of Lender and its successors and assigns.

GENERAL PROVISIONS. Lender may delay or forgo enforcing any of its rights or
remedies under this Note without losing them. Borrower and any other person who
signs, guarantees or endorses this Note, to the extent allowed by law, waive
presentment, demand for payment, and notice of dishonor. Upon any change in the
terms of this Note, and unless otherwise expressly stated in writing, no party
who signs this Note, whether as maker, guarantor, accommodation maker or
endorser, shall be released from liability. All such parties agree that Lender
may renew or extend (repeatedly and for any length of time) this loan or
release any party or guarantor or collateral; or impair, fail to realize upon
or perfect Lender's security interest in the collateral; and take any other
action deemed necessary by Lender without the consent of or notice to anyone.
All such parties also agree that Lender may modify this loan without the consent
of or notice to anyone other than the party with whom the modification is made.
The obligations under this Note are joint and several. If any portion of this
Note is for any reason determined to be unenforceable, it will not affect the
enforceability of any other provisions of this Note.

CONFESSION OF JUDGMENT. BORROWER HEREBY IRREVOCABLY AUTHORIZES AND EMPOWERS ANY
ATTORNEY OR THE PROTHONOTARY OR CLERK OF ANY COURT IN THE COMMONWEALTH OF
PENNSYLVANIA, OR ELSEWHERE, TO APPEAR AT ANY TIME FOR BORROWER AFTER A DEFAULT
UNDER THIS NOTE AND WITH OR WITHOUT COMPLAINT FILED, CONFESS OR ENTER JUDGMENT
AGAINST BORROWER FOR THE ENTIRE PRINCIPAL BALANCE OF THIS NOTE AND ALL ACCRUED
INTEREST, LATE CHARGES AND ANY AND ALL AMOUNTS EXPENDED OR ADVANCED BY LENDER
RELATING TO ANY COLLATERAL SECURING THIS NOTE, TOGETHER WITH COSTS OF SUIT, AND
AN ATTORNEY'S COMMISSION OF TEN PERCENT (10%) OF THE UNPAID PRINCIPAL BALANCE
AND ACCRUED INTEREST FOR COLLECTION, BUT IN ANY EVENT NOT LESS THAN FIVE HUNDRED
DOLLARS ($500) ON WHICH JUDGMENT OR JUDGMENTS ONE OR MORE EXECUTIONS MAY ISSUE
IMMEDIATELY; AND FOR SO DOING, THIS NOTE OR A COPY OF THIS NOTE VERIFIED BY
AFFIDAVIT SHALL BE SUFFICIENT WARRANT. THE AUTHORITY GRANTED IN THIS NOTE TO
CONFESS JUDGMENT AGAINST BORROWER SHALL NOT BE EXHAUSTED BY ANY EXERCISE OF THAT
AUTHORITY, BUT SHALL CONTINUE FROM TIME TO TIME AND AT ALL TIMES UNTIL PAYMENT
IN FULL OF ALL AMOUNTS DUE UNDER THIS NOTE. BORROWER HEREBY WAIVES ANY RIGHT
BORROWER MAY HAVE TO NOTICE OR TO A HEARING IN CONNECTION WITH ANY SUCH
CONFESSION OF JUDGMENT AND STATES THAT EITHER A REPRESENTATIVE OF LENDER
SPECIFICALLY CALLED THIS CONFESSION OF JUDGMENT PROVISION TO BORROWER'S
ATTENTION OR BORROWER HAS BEEN REPRESENTED BY INDEPENDENT LEGAL COUNSEL.

PRIOR TO SIGNING THIS NOTE, BORROWER READ AND UNDERSTOOD ALL THE PROVISIONS OF
THIS NOTE, INCLUDING THE VARIABLE INTEREST RATE PROVISIONS. BORROWER AGREES TO
THE TERMS OF THE NOTE.

BORROWER ACKNOWLEDGES RECEIPT OF A COMPLETED COPY OF THIS PROMISSORY NOTE.

THIS NOTE IS GIVEN UNDER SEAL AND IT IS INTENDED THAT THIS NOTE IS AND SHALL
CONSTITUTE AND HAVE THE EFFECT OF A SEALED INSTRUMENT ACCORDING TO LAW.

BORROWER:

CREATIVE ENTERPRISES INTERNATIONAL, INC.

By: /s/ Michael Salaman                      (Seal)
    -----------------------------------------
    MICHAEL SALAMAN, PRESIDENT & SECRETARY OF
    CREATIVE ENTERPRISES INTERNATIONAL, INC.

================================================================================
                               [FOOTER ILLEGIBLE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]